Chronic Myeloproliferative Disorders Completed Phase 1 / 2 Trials for Methotrexate (DB00563)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00245037Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerTreatment
NCT00049634Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative DisorderTreatment
NCT00054340Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderSupportive Care
NCT00089037Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationSupportive Care